Structural basis for DARC binding in reticulocyte invasion by Plasmodium vivax

The symptoms of malaria occur during the blood stage of infection, when the parasite replicates within human red blood cells. The human malaria parasite, Plasmodium vivax, selectively invades reticulocytes in a process which requires an interaction between the ectodomain of the human DARC receptor and the Plasmodium vivax Duffy-binding protein, PvDBP. Previous studies have revealed that a small helical peptide from DARC binds to region II of PvDBP (PvDBP-RII). However, it is also known that sulphation of tyrosine residues on DARC affects its binding to PvDBP and these residues were not observed in previous structures. We therefore present the structure of PvDBP-RII bound to sulphated DARC peptide, showing that a sulphate on tyrosine 41 binds to a charged pocket on PvDBP-RII. We use molecular dynamics simulations, affinity measurements and growth-inhibition experiments in parasites to confirm the importance of this interaction. We also reveal the epitope for vaccine-elicited growth-inhibitory antibody DB1. This provides a complete understanding of the binding of PvDBP-RII to DARC and will guide the design of vaccines and therapeutics to target this essential interaction. Plasmodium vivax is one of the major causes of human malaria. To replicate, it must get inside human blood cells, in a processing requiring binding of the parasite PvDBP protein to the human DARC receptor. This study reveals how PvDBP binds to DARC and will guide future vaccine design.

Automated summary

The symptoms of malaria occur during the blood stage of infection, when the parasite replicates within human red blood cells. In this study, the researchers investigated the interaction between the human DARC receptor and the Plasmodium vivax Duffy-binding protein (PvDBP) during the invasion of reticulocytes. They found that a sulphate on tyrosine 41 of DARC binds to a charged pocket on PvDBP, confirming the importance of this interaction. The research also identified the epitope for vaccine-elicited growth-inhibitory antibody DB1, providing valuable information for the design of vaccines and therapeutics to target this essential interaction.